On September 14, 2026, the registry for trial NCT05339529 listed its status as completed. The trial, titled "Protective Effect of Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)," examines thymosin alpha-1 in patients undergoing acute aortic dissection surgery. The listed phase is not applicable. Thymosin alpha-1 remains classified as an unapproved research compound.
This update reflects only a change in the trial's recorded status on the registry. No results have been reported alongside this status change in the available data. The completion designation indicates the study has concluded its planned activities as tracked by ClinicalTrials.gov, but it does not by itself indicate what, if any, findings were produced. Readers should not interpret this status update as confirmation of safety, efficacy, or any specific outcome related to thymosin alpha-1 use in this surgical context.
Further detail, including any eventual results, would be reflected in future updates to the same registry entry. For background on thymosin alpha-1 as a compound, readers can consult the compound overview for additional context.